FDA Accepts Zealand's GLP-1 Drug Lixisenatide for Review

By Cormac SheridanStaff Writer

Tuesday, February 19, 2013

The FDA accepted for review a new drug application for lixisenatide, the once-daily glucagon-like peptide-1 (GLP-1) receptor agonist Zealand Pharma A/S has developed in partnership with Sanofi SA, paving the way for a possible U.S. approval in Type II diabetes by early 2014.